Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. It offers a range of APIs for use in amyotrophic lateral sclerosis, anti-inflammatory, anti-allergic, anti-asthmatic, anticoagulant, anti-convulsant, anti-diabetic, anti-emetic, anti-fungal, anti-gout, anti-migraine, ARV and anti-viral, benign prostate hyperlasia, cardiovascular, erectile dysfunction, expectorant, expectorant, gastro-intestinal, genitourinary, hyperparathyroidism, immunology and inflammation, multiple sclerosis, muscle relaxant, neuropsychiatry, oncology, ophthalmic, osteoporosis, steroid, and urinary incontinence products. This segment also offers contract research services to biotech and pharmaceutical companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. It offers a portfolio of branded generics in the therapeutic areas of gastro-intestinal, cardiovascular, central nervous system, pain management, oncology, anti-infective, hormones, urology, respiratory, gynecology, pediatrics, and dermatology. The Proprietary Products segment engages in the discovery and development of new chemical entities for subsequent commercialization and out-licensing. This segment also focuses on developing differentiated formulations and biosimilars. The company primarily operates in India, the United States, Russia and other CIS countries, Germany, the United Kingdom, Venezuela, South Africa, Romania, and New Zealand. Dr. Reddy’s Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.